Theregen Inc.

Development of cellular therapies for the treatment of cardiovascular diseases

Theregen, formerly named IKEN Tissue Therapeutics, was formed as a biotechnology company with focus on regenerative medicine in 2003 by Michael Siani-Rose and H. Martin Lades. One year later, Theregen adopted the Cardiovascular R&D sector of the company Advanced Tissue Sciences (ATS) comprising its Anginera technology that is currently produced by Smith & Nephew plc.

Michael Siani-Rose, President and Founder
Paul Quadros, CEO
Gary D. Gentzkow, M.D., CMO
Gilbert R. Mintz, Ph.D., Licensing and Business Development

Gail K. Naughton, Ph.D., Chairman
Robert C. Robbins, M.D.
Judith L. Swain, M.D.
Stuart K. Williams, Ph.D.
Robert S. Kellar, Ph.D.

225 Bush St. 16th Flr.
San Francisco, CA 94105
USA
Phone: +1-415-439-8320
Fax: +1-415-738-2383

Theregen’s lead product Anginera™ targets the fields of regenerative medicine, especially cardiovascular and vascular diseases. Anginera™ is a cell-based wound care system, e.g. used in cardiac surgery. Patches comprising fibroblast cells are placed on injured vessels and diseased tissue of the heart muscle effecting the stimulation of new vessel growth by secreted cytokines and growth factors.

In July 2005, Theregen started a Phase I safety trial for the use of Anginera™ in coronary arterial bypass graft surgery. This study is currently undergoing clinical testing.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.